Shared on 15 Oct 25
Fair value Decreased 1.18%Analysts have modestly lowered their price target for GE HealthCare Technologies from $88 to approximately $86.96 per share, citing incremental shifts in fair value and ongoing market uncertainties, such as evolving conditions in China and sustained concerns over order books. These factors are balanced by encouraging updates to the company’s product pipeline.
Shared on 30 Apr 25
Fair value Decreased 2.19%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 0.15%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 1.06%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.33%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 0.089%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 0.22%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 0.71%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 14%AnalystConsensusTarget has decreased revenue growth from 4.2% to 3.7%.